How to Slash the Cost of Drug Development
scientificamerican.com
scientificamerican.com
It has done this with US$290 million—about one-quarter of what
a typical pharmaceutical company would spend to develop just
one drug. The model for its success is the product development
partnership (PDP), a style of non-profit organization that
became popular in the early 2000s. PDPs keep costs down
through collaboration—with universities, governments and the
pharmaceutical industry.
So, was the $290 million the total amount for all 26 trials? Or did the collaborators kick in money? Because otherwise this is like claiming you've found a way to buy a new Tesla for $1000-- as long as your parents pay the other $69,000! Drug development from scratch is arduous and expensive. It
begins with experiments on hundreds of thousands of
chemicals in the lab, looking for one that kills a pathogen
without harming the host.
The article does not go out of its way to mention that this isn't the expensive and arduous part. The clinical trials are what's expensive, since you have to pay thousands of people, who have the disease you're targeting, to take your experimental drug. In many cases, they have to take your drug instead of a drug that's known to work. And you have to follow these people for years, just in case they don't all suddenly get liver cancer and die a year after they stop taking your drug. (Something like this cost Merck $4.85 billion dollars in 2004: https://en.wikipedia.org/wiki/Rofecoxib ) The final trials on fexinidazole conclude this year, and
Wourgaft is hopeful that the data will earn regulators'
stamp of approval. The project has so far cost the DNDi
about $45 million—and it stands to help 21 million people at
risk of the disease in Africa.
Which regulators? There is a rather huge difference between the FDA and the Central African Republic's FDA-equivalent. Is this how they're saving money on clinical trials, by running clinical trials on Africans, and only getting regulatory approval from African states?Granted, motivation makes a big difference here. However it's often hard to tell profit motive from innate motive, especially in a legal context. What starts off as innate can quickly become profit-oriented (or even worse "I told you so"-oriented) behind closed doors when stuff hits the fan.
Running unregulated clinical trials in impoverished nations makes a corporate comeback.
It is, but regulated trials in such countries have real scientific advantages. The average US patient (older, overweight, probably diabetic) swims in a cocktail of drugs ranging from painkillers[1] to cholesterol reducers. By some estimates 60% of American adults are on one or more prescription drugs, a percentage that no doubt climbs with age. That makes them difficult guinea pigs for the study of new treatments. But the average African cannot afford such cocktails and so is most likely clean of other drugs. Costs and poverty aside, if you are looking for a drug-free study population, Africa is easier than the west.
[1] "In 2010, enough prescription painkillers were prescribed to medicate every american adult every 4 hours for 1 month."
https://www.drugabuse.gov/related-topics/trends-statistics/i...
Most drug effectiveness is related to the population in which it is deployed, based on their combination of unique risk factors and etiologies. Socioeconomic factors (and I mean that in its accurate usage, not just a short-hand for "income") are a huge example: they're one of the biggest predictors of health outcomes and responsiveness to various treatments, and using a population with wildly different SES factors fundamentally kills the trial.
A sample population which accurately reflects the general population in which a drug is to be deployed is assessed, in clinical trials, as something known as "external validity" (as opposed to "internal validity", which is just whether the experiment is properly designed to test its stated hypothesis).
tl;dr apparent drug effects in Africans are not useful indicators of drug effects in Americans, particularly if your premise is "those drugs have different outcomes in Americans."
You need a baseline for any testing. When testing physical equipment with a difficult to diagnose problems the easiest way to figure out what is going on is to take the hardware down to a base state and then add one component at a time to see where things go wrong. When you have one population that is positively effected by your drug and takes no other medications it gives a great deal of insight when another population is negatively effected that is highly medicated.
We have a problem here in the U.S. that almost all of our old drugs would never be approved these days because of interactions with other drugs and side effects. With the huge amount of medications taken we need the baseline to tell doctors to stop giving patients drugs X, Y, and Z because they would be much better off only taking A.
That's a huge exaggeration. There are maybe a handful of drugs where the side effects/interactions are so bad that they wouldn't be approved by today's FDA.
As others have said, many drug studies are looking for a degree of effect, whether the drug out performs some other drug already in use. For such comparisons you need a baseline effect. The US population's drug consumption, while certainly the eventual market, is a shifting target. If you want a common baseline for comparisons, the easiest is a drug-free test subject.
Also, drugs are tested on groups but administered to individuals. A prescribing doc needs to know the effect absent any other drug interactions. Having a patient stop taking other drugs is always an option. So you need an understanding of how the drug operates under ideal conditions and in the presence of other drugs. Prescriptions remain an individualised medical choice.
You raise a great point. I was talking to a CRO (contract research organization - often hired to run clinical trials) and the rule of thumb is that a phase 3 trial will cost ~$10K to $15K per patient per year. It all depends on how involved the endpoint measurements are. A simple blood test pushes it to the lower part of that range and something more involved like an MRI might push it to the top (or higher).
That doesn't seem bad until you start to look at the size and duration of trials. If you're coming up with a new heart disease drug, the FDA often requires a multi-year trial and 5K to 10K patients in each trial (two phase 3 trial are required by the FDA, generally).
So if you're running two 10,000 patient trials that last 2 years, your phase 3 bill is already $300M. And that doesn't include all the other costs that come with bringing a new drug to market.
Now that is the higher end. Oncology clinical trials or trials for orphan diseases can push that number down to 1/10th or ~$30M.
They are comparing two different things with this statement. You can't compare "bringing something into development" and bringing it to market. Hell, if I move some crap drug into phase one i've "brought it into development". It means nothing.
Also, the one example of a marketed drug they successfully brought to market was a combination of two already approved drugs. The risks are much lower when you don't have to worry about toxicity and ADME.
I'll give them credit for working on a noble cause, but I've seen nothing to suggest they've fixed the challenges of R&D.
(By the way, this story format is getting a little old. The writer obvious has a pitch to make. They make the pitch by talking to selected subjects and using their quotes. Then, in order to somehow assure the reader of balance, they bring in a fall guy about 80% of the way in to say something cranky. Then they dismiss it. It's okay in argumentation, I guess, but really should be rare in straight reporting.)
Note that I'm not saying there isn't something cool here. Beats me. I read the article and have no more of an understanding about drug development than when I began. This felt like one of those articles where an editor runs into a booster at a social event and is told how really cool X is. They get excited. So they tell a writer to go write a story telling folks how really cool X is.
Mission accomplished. But not such a good article, sadly.
The author mentions repeatedly that DNDi got reduced cost access to both high throughput screening, clinical trials, and drug regulation, so they can develop a drug for less cost. No surprise, but how is this a sustainable model for developing most new drugs? What processes have they improved to save money/time that is not dependent on freebies from generous for-profit drug corporations, universities, and governments? Somehow I missed that part.
Personally, I'd dearly love to reduce the cost of drug development and prices. But until DNDi pays the full cost for all of the reagents, processes, and rules in their drug development process, they have no business claiming to have cured the ills that bedevil big pharma. No business at all.
It's the difference between "proving" that changing a button color at Amazon makes people buy 1% more stuff (worth billions, probably) and "proving" it at a start-up. The start-up won't care about 1% more, but if you can triple sales, awesome! Even though tripling sales at a start-up might only be worth $500k, not billions.
When you're making HUGE inroads on efficacy it's much, much easier to demonstrate and you don't need thousands or tens of thousands of patients in the trial in order to get a statistically significant result.
2) The regulatory threshold for efficacy doesn't change just because the drug maker isn't trying to make a profit. They'll still need the same rate of postive outcomes for a drug to get FDA approval. Yes, if a drug is deemed life-saving, the approval criteria may ease to expedite the approval process and lessen the thresholds for efficacy and toxicity. But such fast tracking applies only to critical care drugs and without regard for their potential market size or profitability. The need must be dire and unserved.
Pricing can be very complex topics, people have written whole books about it, like the classic "Strategy and Tactics of Pricing" by Nagle.
In field where marketing and pricing are much less understood, like ours, the trick is that after you establish acceptable pricing for your widgets, you then compare that to all your production, etc. costs to to see if you should keep selling them etc
Note that in many "regions" "big pharma" negotiates the price with a penny punching government
Note also some drugs are inherently expensive to produce, I'm thinking one anti-HIV one that had the usual suspects screaming, but it has 3 chiral centers (ouch!; for a layman's analogy illustration, Derek Lowe wrote a good one using ballons...).
That's one of the reasons why drugs are so expensive in the US--we are one of the few countries to not have government negotiating our side, so pharmaceutical companies have to make their profit here.
"Open Source Drug Discovery" - "collaborative drug discovery platform for neglected tropical diseases like leishmaniasis, which draw limited attention of research, based pharmaceutical enterprises"
https://en.wikipedia.org/wiki/Open_Source_Drug_Discovery
--or --
"Crowdsourcing in pharma: a strategic framework"
http://dx.doi.org/10.1016/j.drudis.2015.01.011
pdf: http://csmres.co.uk/cs.public.upd/article-downloads/Crowdsou...
http://blogs.sciencemag.org/pipeline/archives/2015/04/02/sil... and https://www.quora.com/What-is-the-Andy-Grove-fallacy for details.
How do you think a "start-up" could do that in one or two weeks?
On top of that. things like "open source 3d printable epinephrine injector[s]" are a very dangerous pipe dream. While there is certainly regulatory capture involved, most of the regulations relating to development, manufacturing, and distribution of pharmaceuticals and medical devices are in place for good reasons.
This is everyday of illegal drug import from east to west in Europe, but thanks to Shengen EU's border saw some tightening in recent years, and so number of "cheaper alternative drugs" is at minimum these days.